Azalea launched with promise to deliver off-the-shelf genome engineering

California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary enveloped delivery vehicle (EDV) technology.

The company’s mission is to engineer therapeutic cells with precision directly inside the patient, transforming how cell and gene therapies are created and delivered.

Azalea’s EDV technology selectively targets cells, delivering transient CRISPR-Cas9 cargo to mediate programmable genome editing. Combining this with a highly efficient T cell-tropic AAV to deliver a promoterless homology-directed repair template enables programmable, site-specific large gene insertion at defined genomic sites within the T cell.